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Summary Epithelial ovarian cancer is known to aggregate in families. The dominantly inherited ovarian cancer predisposing genes, BRCA1,
BRCA2and genes involved in the hereditary non-polyposis colorectal cancer (HNPCC) syndrome, have recently been identified. However, in
the majority of families with more than one case of ovarian cancer, dominant inheritance cannot be recognized. We investigated familial
clustering of epithelial ovarian cancer in a population-based sample of 663 Finnish ovarian cancer patients. A segregation analysis with the
POINTER software was conducted on the 937 nuclear families from these 663 pedigrees. The major gene model was favoured, and the
sporadic and multifactorial models were strongly rejected. In the studied population, the best fitting model was a recessive mode of
inheritance, and 8% of ovarian cancer patients were estimated to be homozygous forthe deleterious genotype. This evidence for recessively
inherited ovarian cancer predisposition should be interpreted cautiously, as the analysis is subject to certain errors, which are discussed in the
article. Results of this analysis, however, strongly emphasize the role of genetic factors in all familial aggregation of epithelial ovarian cancer.
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Epithelial ovarian cancer aggregates in families. Evidence for this
comes from two sources: epidemiological case-control studies, in
which the first-degree relatives of ovarian cancer patients have
been observed to have a two- to fivefold increased risk forovarian
cancer (Hartge et al, 1989; Schildkraut et al, 1989; Parazzini et al,
1992; Houlston et al, 1993; Goldgar et al, 1994; Hartge et al, 1994;
Kerber and Slattery, 1995); and from family studies, which have
identified families prone to ovarian cancer or, more commonly, to
ovarian and breast cancer (Liber, 1950; Lewis and Clare Davidson,
1969; Li et al, 1970; Lynch et al, 1974; Fraumeni et al, 1975; Thor
et al, 1976).
In family studies, cancer predisposition appears to be trans-
mitted as an autosomal dominant trait, and a segregation analysis
on ovarian cancer, based on data obtained from healthy women
attending a family cancer unit, supports this observation (Houlston
et al, 1991). The search for a dominantly inherited gene causing
both breast and ovarian cancer predisposition has led to the isola-
tion of the genes BRCAJ (Miki et al, 1994) and BRCA2 (Wooster
et al, 1995), mutations of which have now been estimated to be
involved in the majority of families with either site-specific
ovarian cancer or breast-ovarian cancer predisposition (Steichen-
Gersdorf et al, 1994; Narod et al, 1995).
Although families with multiple affected members stand out as
examples of inherited cancer predisposition, the most common
form of familial ovarian cancer is the occurrence of only two
ovarian cancercases in the family, without recognizible features of
dominant inheritance (Greggi et al, 1990; Grover et al, 1993; Piver
et al, 1993). This type offamilial ovarian cancer contributes to the
majority of the risk increase observed in the first-degree relatives
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of ovarian cancer patients (Schildkraut and Thompson, 1988;
Parazzini et al, 1992). To what extent familial ovarian cancer can
be explained by mutations in the BRCAJ and BRCA2 genes or
mutations in the other known dominantly inherited cancer-predis-
posing genes, most importantly those involved in the hereditary
non-polyposis colorectal cancer(HNPCC; Aaltonen etal, 1994), is
unresolved.
We have examined the familial occurrence of ovarian cancer
among a Finnish population by conducting a complex segregation
analysis (Lalouel and Morton, 1981) on an unselected sample of
Finnish ovarian cancer patients. We have had the advantage of
using data obtained from population registries and the Finnish
Cancer Registry; therefore, the data used is completely verified
from genealogical registries and medical records. With this
population-based design, we were able to avoid major biases in
relation to patient selection and cancer reporting.
MATERIALS AND METHODS
Ascertainment of the families
The data on patients, from here on referred to as the probands,
were obtained from the Finnish Cancer Registry. The population-
based and nationwide Finnish Cancer Registry has been operating
since 1953 registering over 99% of all solid tumours in Finland
(Teppo et al, 1994). All patients, who had an epithelial ovarian
cancer diagnosed during the years 1980 to 1982 and who were
under 76 years of age at the time of diagnosis were selected as
probands. Patients with a borderline ovarian tumour were
excluded. Altogether, there were 863 probands.
The method ofdata collection has been described in detail else-
where (Auranen et al, 1996). Briefly, the local registries of the
communities where the probands were born were contacted to
obtain the names and birth dates ofparents and siblings. In cases in
which the family had moved to another community, tracing was
15371538 A Auranen andL Iselius
Table 1 Liability classes and morbid risks in Finland 1973-1982
Class Age range Cumulative Cumulative Morbid risk
(years) incidence mortality
1 Males 0.00001a
2 Females 20-29 0.00044 0.00010 0.00030
3 Females 30-39 0.00110 0.00022 0.00100
4 Females 40-49 0.00288 0.00097 0.00266
5 Females 50-54 0.00430 0.00172 0.00334
6 Females 55-59 0.00616 0.00282 0.00445
7 Females 60-64 0.00823 0.00424 0.00543
8 Females 65-69 0.01051 0.00583 0.00630
9 Females 70+ 0.01538 0.00766 0.00961
aMales given a very low value for program reasons.
continued until either of the parents deceased or the mother
reached 50 years of age and further pregnancies were considered
unlikely. Altogether, 700 (81%) ofthe probands' family members
were traced. Failure to trace the family members resulted from
inability to find the proband from the population registries of her
reported birthplace (90 patients), lack of response from local offi-
cials (25 patients), born abroad (five patients) or failure to follow
the family until additional children were considered unlikely,
caused by the fact that the family changed location repeatedly (43
patients). In addition, data on the probands' husband and children
were obtained from the parishes.
The relatives ofthe 700 probands were followed up until death
orto theend of 1993, whichever was first. The cancer morbidity of
the relatives was checked from the files of the Finnish Cancer
Registry. As the Finnish Cancer Registry has been operating only
from the beginning of 1953, the cancer status ofthe male relatives
deceased before this was classified as unknown. For mothers and
sisters deceased during 1936-1952, death certificates were
obtained, and their cancer classification was based on deathcertifi-
cate information. For women deceased before 1936, death certifi-
cates were not available, and their cancer status was classified as
unknown. Cancer status was also classified as unknown for the
273 relatives, who were lost during the follow-up.
For 37 ofthe 700 probands, family information was incomplete
in the sense that all female relatives were classified as having an
unknown cancer status. As these families could not contribute to
the analysis, they were excluded. In consequence, the final data set
included 663 probands, who had the following relatives (number
of unknown ovarian cancer phenotypes in brackets): 663 mothers
(101), 663 fathers, 1339 sisters (153), 1333 brothers, 459 daugh-
ters (18) and 322 sons. The age of the daughters included in the
analysis ranged from 20 to 68 years.
Segregation analysis
The 663 ovarian cancer pedigrees were partitioned into 937
nuclear families. The families were oftwo types: (1) sibships with
the proband as a child (single selection, 663 families); and (2) chil-
dren of the proband (complete selection, 274 families). Females
below the age of20 years were excluded from the genetic analysis.
For single selection, the ascertainment probability pi was taken as
0.001. There were no pointers in the material.
Segregation analysis was carried out under a mixed model using
the computer program POINTER (Lalouel and Morton, 1981). The
mixed model assumes an underlying scale of genetic liability to
which amajorlocus, polygenes andenvironmental factors operate.
The effects are assumed to be independent and normally distrib-
uted. The parameters to be estimated are H: multifactorial
heritability, q: gene frequency at the major locus; d: degree of
dominance; and t: the displacement between the two heterozygous
means. A recessive gene corresponds to d = 0 and a dominant to
d = 1. Additivity corresponds to d = 0.5. The gene frequency
was assumed to remain constant throughout all age classes.
Being affected was defined by a threshold on the liability scale.
As liability to ovarian cancer varies with age, females were
assigned to one of eight liability classes based on age (Table 1).
All male relatives were given a morbidriskof0.00001. The risk of
ovarian cancer attributed to thejth liability class was defined by
Iselius et al (1991):
I. - M.
I-M.j,
where I. is the cumulative incidence to the mid-point ofj and M.
is the cumulative specific mortality to the end of the preceding
class. R. is therefore the probability that an individual observed in
the jth class (dead or alive) is affected. The incidence (1) and
mortality (M) of ovarian cancer were taken from the Finnish
Cancer Registry for 1973-1982. Individuals with borderline
ovarian tumours were considered normal in the present analysis.
For estimation of the parameters, conditional likelihood was
used. To test between the hypotheses, minus twice the log likeli-
hood (-21n L + C, where C is a constant) calculated under the
general model was subtracted from the likelihood for a restricted
model (with one ormore parameters heldconstant). Thedifference
is distributed as a chi-square with the appropriate number of
degrees offreedom.
The penetrances (P) for different age groups were calculated
using the formulas given by Iselius et al (1991):
P. = P (aff G',j) + [1-P(aff G',j)] M 1,
where the genotype-specific mortality is
j-l
M1 = { P(G'I aff, i) (M=-M 1)) / P(G' aff, i) (I -I )
i= 1
In the formula, G' stands for the disease gene.
RESULTS
Altogether, the 663 ovarian cancer probands had 31 first-degree
relatives affected with ovarian cancer: 23 ovarian cancer probands
had one affected relative and four probands had two affected rela-
tives. In 23 of these 27 families, only sisters were affected. These
families included three of the families with three ovarian cancers
but, in one ofthese families, the motherhad an abdominal cancerof
unknown origin. In the analysis, she was defined as unaffected.
Breast cancer was present in 10 ofthe 23 families with two ovarian
cancer cases but, in only four families, the age ofthe patient at the
time ofbreastcancerdiagnosis was less than 55 years. Breast cancer
was not present in the four families with three ovarian cancercases.
Ofthe 23 families with affected sisters only, in two families the
mother had an unknown cancer phenotype and in one family the
mother had breast cancer diagnosed at the age of 75 years. The
remaining 20 mothers were not diagnosed with ovarian or breast
cancer; all but one lived to be over 50 years ofage and 13 ofthem
over 70 years ofage.
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Table 2 shows the results of the complex segregation analysis.
The sporadic model, i.e. a model in which any familial occurrence
of ovarian cancer is purely due to chance, was strongly rejected
(x23= 41.55, P <0.001). Also, the multifactorial model was
rejected in favour of a major gene (x23= 14.12, P <0.001). The
best fitting model was a recessive gene with a gene frequency of
0.0221. For all major gene models, H went to zero when iterated.
There was no evidence for an additional familial component. We
were not able to find any heterogeneity with regard to degree of
dominance when the families were partitioned according to the
mode ofascertainment and mating type (results not shown).
Characteristics ofthe major locus are given in Table 3. Lifetime
penetrance for the deleterious genotype is estimated to be 90%.
Taken over all liability classes, the probability of being homozy-
gous for the recessive gene, given affection, is 0.079. The proba-
bility ofan affected woman between 20 and 29 years ofage having
the deleterious recessive genotype is 0.57, while thecorresponding
probability is 0.06 for a woman in her seventies.
DISCUSSION
After the identification of the breast and ovarian cancer-predis-
posing genes, BRCAJ and BRCA2, it has been possible to demon-
strate that a large majority of the families with both breast and
ovarian cancer patients segregate mutations of these genes, espe-
cially BRCAI mutations (Narod et al, 1995). However, there is
evidence from studies estimating the contribution of BRCAJ
and BRCA2 genes to ovarian cancer incidence, that additional
ovarian cancer-predisposing genes might exist (Ford et al, 1995;
Whittemore et al, 1997).
The results of this segregation analysis differ from the previ-
ously presented segregation analysis of ovarian cancer (Houlston
et al, 1991) and from whatis generally known ofthe inheritance of
ovarian cancer (Claus and Schwartz, 1995) in the respect that a
Table 2 Results of the segregation analysis
Hypothesis -21nL + C H q t d
Sporadic -7632.20 (0) (0) (0) (0)
Multifactorial -7659.63 0.33 (0) (0) (0)
Recessive -7673.75 0 0.0221 3.26 (0)
Additive -7666.94 0 0.000568 4.36 (0.5)
Dominant -7666.95 0 0.000574 2.18 (1)
Table 3 Characteristics of the major locus for each female liability class
under the best fitting recessive model (d= 0, q = 0.0221, t= 3.26)
Age range P(affection/genotype) P(G'G/affection) Penetrance (P)
(years)
G'G' GG' or GG
20-29 0.353 0.00013 0.566 0.73a
30-39 0.536 0.00074 0.262 0.66
40-49 0.670 0.00233 0.124 0.75
50-54 0.699 0.00300 0.103 0.79
55-59 0.734 0.00409 0.081 0.82
60-64 0.757 0.00506 0.068 0.85
65-69 0.774 0.00592 0.060 0.87
70+ 0.819 0.00921 0.042 0.90
aThis number is based on very few cases.
recessive mode of inheritance is strongly favoured. The main
result ofthis analysis is complementary to ourprevious analysis of
this material using a different method (Auranen et al, 1996). We
estimated the cancer incidence in these first-degree relatives of
ovarian cancer patients and found that the incidence of ovarian
cancer increased in sisters only. The incidence decreased both by
the age of the sister and by the age of the proband at diagnosis,
suggesting the involvement ofagenetic component.
There are three main problems in this analysis that might have
influenced the results. The first concerns possible underascertain-
ment of ovarian cancer cases in the maternal generation. The
cancer phenotype was unknown for 16% of the mothers; this,
however, did not have a significant impact on the results.
Additionally, 20% of the mothers had died before 1952. National
cancer mortality and incidence statistics are available in Finland
only from the beginning of 1953, which means that we were
unable to estimate possible underdiagnosis of cancer in the
maternal cohort. If there was severe underdiagnosis of ovarian
cancer cases in these mothers, this has inevitably affected the
results in favour of a recessive mode ofinheritance.
The second problem relates to liability class estimates. We
constructed liability classes accounting for morbid risks. A similar
approach has also been used by a previous segregation analysis on
ovarian cancer (Houlston et al, 1991). It would be advisable to
construct liability classes on the basis of survival functions, but
currently this is not possible with the POINTER software.
We have also used the same liability class estimates for both
mother and proband generations, which means that we have not
allowed for secular trends in ovarian cancerrisk. The age-adjusted
incidence rate of ovarian cancer in Finland has only slightly
increased with time: it was 9.9 per 100 000 person-years in the 5-
year period 1961-1966 and 12.7 per 100 000 person-years in the
5-year period 1986-1990 (Finnish Cancer Registry, 1995). As the
age range oftheprobands in this study ranged from 20 to 75 years,
the oldest probands were born before the mothers of the youngest
probands. Instead of giving different baseline liability estimates
for mother and proband generations, it would have been more
justified to give liability estimates according to birth year. This
was not considered to be necessary because ofonly slight changes
in the ovarian cancer incidence rates over time.
The third problem in our analysis is inability to take into
account the occurrence of breast cancer in the family. When we
estimated breast cancer incidence in this cohort (Auranen et al,
1996), the observed number of breast cancers was exactly the
number that was expected, but there was some co-aggregation of
breast and ovarian cancer. It is presumed that some ofthe families
with two or more ovarian cancer cases harbourBRCAI or BRCA2
gene mutations, especially some ofthe ten families that also had a
breast cancer case in a close relative.
Because of the above problems, the results pointing to a
recessive ovarian cancer predisposition should be interpreted
cautiously. The possibility of recessive inheritance of ovarian
cancer has only rarely been suggested previously, based either on
consanguinity (Cramer et al, 1983) or on higher ovarian cancer
mortality in sisters compared with mothers of ovarian cancer
patients (Easton et al, 1996).
A detailed inspection of some of the previously published
family studies reveals that families with more than one case of
ovarian cancer can be roughly categorized into three groups: (1)
families with ovarian and breast cancer in two or more generations
(Li et al, 1970; Thor et al, 1976; Franceschi et al, 1982; Greggi et
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al, 1990; Narod et al, 1994); (2) families with only ovarian cancer
in two or more generations (Liber, 1950; Lewis and Clare
Davidson, 1969; Li et al, 1970; Fraumeni et al, 1975; Thor et al,
1976; Lurain and Piver, 1979); and (3) families with ovarian
cancer in sisters only, without breast orother cancers (Kimbrough,
1929; Molloy, 1970; McCrann et al, 1974; Fraumeni et al, 1975;
Skinner et al, 1977; Franceschi et al, 1982; Greggi et al, 1990;
Narod et al, 1994). In the Gilda Radner Familial Ovarian Cancer
Registry, mother-daughter relationships represented 50% of the
families, but sister-sister relationship was the second most
frequent type of relationship and represented 39% of all families
(Piver et al, 1993).
It is possible that inherited predisposition to epithelial ovarian
cancer is caused by heterogeneous mechanisms: the dominantly
inherited cancer-predisposing genes, BRCAJ and BRCA2, which
are most likely involved in families with breast cancer and fami-
lies with ovarian cancer in two or more generations, and some
other, possibly recessively inherited cancer-predisposing genes,
in families without features of dominant inheritance. In support
of this are the results from a segregation analysis of the CASH
study, in which the existence of both shared and unique genes
predisposing to breast and ovarian cancer were deduced
(Schildkraut et al, 1989).
Another possibility is that mutations in the known ovarian
cancer-predisposing genes, BRCAJ and BRCA2, have diversified
effects on the phenotype of a mutation carrier, and the typical
cancer families represent only the most severe forms of cancer
susceptibility. If so, identification ofBRCAJ and BRCA2 mutation
carriers on the basis offamily history ofcancer, as well as genetic
counselling offamilies, might be difficult.
The Finns are a small population that have lived as a genetic
isolate for over 2000 years. As a result ofthis isolation, the genetic
drift has led to the enrichment ofcertain recessive genes, whereas
some genetic diseases common elsewhere have nearly disappeared
(de la Chapelle, 1993). The results ofthis segregation analysis are,
therefore, valid only in the Finnish population, and similar studies
from other populations are needed. It would be especially impor-
tant to analyse data that are not biased towards younger ovarian
cancer probands, as has been the case in many of the previous
studies (Schildkraut et al, 1989; Easton et al, 1996).
A search for BRCAI and BRCA2 gene mutations in the familial
ovarian tumours in this material is currently under way. This
should show us how many ofthese 27 families with multiple cases
of ovarian cancer are affected by mutations in these genes. If
BRCAJ or BRCA2 mutations are not detected in a considerable
proportion of these familial ovarian tumours, molecular genetic
studies aiming to find yet unidentified, possibly recessively
inherited genes for ovarian cancer predisposition are greatly to
be encouraged.
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